Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CVS Health Corp (NY:CVS)

69.66 +0.68 (+0.99%)
Streaming Delayed Price Updated: 2:49 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CVS Health Corp

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
58 59 Next >
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
CVS Health (CVS) Q1 2024 Earnings Call Transcript
CVS earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and... 
Via Talk Markets
Topics Economy Stocks
Why CVS Health Stock Plunged Today
Its profits took a hit as its insurance benefit payouts rose. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in CVS Health
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Is This Beaten-Down Dividend Stock a Buy?
The company has one major strength: It offers essential services. 
Via The Motley Fool
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Looking Into CVS Health's Recent Short Interest
Via Benzinga
CVS Shares Dump On Earnings Miss, Outlook Slashed On Rising Medical Costs
CVS shares plunged after first-quarter revenue and adjusted earnings missed Wall Street's average expectations. The drugstore chain also slashed its full-year profit outlook, citing rising medical... 
Via Talk Markets
Topics Earnings
CVS Stock Earnings: CVS Health Misses EPS, Misses Revenue for Q1 2024
CVS stock results show that CVS Health missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Rising Cost For Health Insurers Bites CVS Health's Q1 Profit, Stock Tanks
CVS Health Q1 sales of $88.4 billion, up 3.7% Y/Y. Adjusted EPS at $1.31, down from $2.20. Health Care Benefits segment sees strong growth, while Health Services segment faces challenges. Revised 2024... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
CVS Health Dives To 3-Year Low On Medicare Cost Surge
CVS earnings tumbled more than expected on a surge in Medicare costs. 
Via Investor's Business Daily
Humana Leaves Shareholders in Limbo on 2025 EPS Guidance
Health insurer Humana reported Q1 2024 earnings, getting a less dramatic reaction than its Q4 2023 report, causing shares to tumble more than 13%. 
Via MarketBeat
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) 
Via Benzinga
Topics Economy
CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?
CVS stock is making its way above Walgreens as a potential watchlist addition. Fundamentals and price targets see the stock making a comeback this year. 
Via MarketBeat
Walmart Pulls Plug On Health Centers, Telehealth; Respite For TDOC?
Walmart is shutting down its health centers and virtual care offering, continuing a broader shakeup in telehealth. WMT stock is near a buy point. 
Via Investor's Business Daily
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
The company is projected to bring in increasing sales through at least 2029. 
Via Investor's Business Daily
DoorDash: 5 Compelling Reasons to Buy the Dip
DoorDash Inc. (NASDAQ: DASH) is the leading restaurant and food delivery service in the United States - should you buy the dip? 
Via MarketBeat
Topics Death
3 Value Stocks to Buy on the Dip: April 2024
With the tech sector fallout leading to some red ink, here are the value stocks to buy on the dip for astute investors. 
Via InvestorPlace
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly. 
Via Benzinga
5 High-Yielding Oversold Stocks with Bullish Ratings
Investors have favored defensive sectors in the short term, and oversold high-yielding names might become more in play as tensions rise and the market pulls in. 
Via MarketBeat
Topics Economy
7 blue chip stocks to Buy on the Dip: April 2024
Each of these seven blue-chip stocks to buy on the dip offer high-quality at a more-than-reasonable price. 
Via InvestorPlace
3 Absurdly Cheap Stocks to Buy and Hold for Years
These stocks all deserve to be trading at far higher prices, and it may not be too long before they start to rally. 
Via The Motley Fool
Put $5,000 in These 7 Blue-Chip Stocks Today
If you’re looking for reliability, jump into safer blue-chip stocks. They’re not all exciting, but they have proven to be ultra-reliable. 
Via InvestorPlace
Beat the Dow Jones With This Cash-Gushing Dividend Stock
The change in interest rate expectations has created a big opportunity for patient investors. 
Via The Motley Fool
Topics Stocks
The Smartest Dividend Stocks to Buy With $400 Right Now
These stocks all offer growing and generous dividends. 
Via The Motley Fool
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically." 
Via Investor's Business Daily
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback